zileuton trade name zyflo orally active inhibitor thus inhibits leukotrienes formation used maintenance treatment asthma zileuton introduced abbott laboratories marketed two formulations cornerstone therapeutics inc brand names zyflo zyflo cr original immediaterelease formulation zyflo taken four times per day extendedrelease formulation zyflo cr taken twice daily although mg immediate release tablet zyflo extended release formulation zileuton still available zyflo cr mg immediate release tablet withdrawn us market february zileuton indicated prophylaxis chronic treatment asthma adults children years age older zileuton indicated use reversal bronchospasm acute asthma attacks therapy zileuton continued acute exacerbations asthma recommended dose zyflo one mg tablet four times per day tablets may split half make easier swallow recommended dose zyflo cr two mg extendedrelease tablets twice daily within one hour morning evening meals daily dose mg split zyflo cr tablets half related compounds include montelukast singulair zafirlukast accolate two compounds leukotriene receptor antagonists block action specific leukotrienes zileuton inhibits leukotriene formation research mice suggests zileuton used alone combination imatinib may inhibit chronic myeloid leukemia also researched mouse model serious side effect zyflo zyflo cr potential elevation liver enzymes patients therefore zileuton contraindicated patients active liver disease persistent hepatic function enzymes elevations greater three times upper limit normal hepatic function assessed prior initiating zyflo cr monthly first months every months remainder first year periodically thereafter neuropsychiatric events including sleep disorders behavioral changes may occur zyflo zyflo cr patients instructed notify healthcare provider neuropsychiatric events occur using zyflo zyflo cr zileuton weak inhibitor thus three clinically important drug interactions include increasing theophylline propranolol levels shown lower theophylline clearance significantly doubling auc prolonging halflife nearly theophyllines relation caffeine methylxanthine theophylline metabolite caffeine caffeines metabolism clearance may also reduced drug interaction studies zileuton risomer warfarin metabolism clearance mainly affected zileuton sisomer metabolism via different enzymes lead increase prothrombin zileuton active oral inhibitor enzyme forms leukotrienes acid acid arachidonic acid chemical name zileuton molecular formula zileuton molecular weight formulation manufacturer racemic mixture r following oral administration zileuton rapidly absorbed mean time peak blood serum concentration hours average halflife elimination hours blood plasma concentrations proportional dose whereas absolute bioavailability unknown apparent volume distribution zileuton approximately lkg zileuton bound plasma proteins primarily albumin minor binding glycoprotein elimination zileuton primarily metabolites urine feces accounting next largest amount drug metabolized cytochrome enzymes common adverse reactions reported patients treated zyflo cr sinusitis nausea pharyngolaryngeal pain vs placebo respectively zileuton minor substrate weak inhibitor cyp drug shown increase serum concentration effects theophylline propranolol warfarin although significant increase prothrombin time obvious advised doses medication monitored andor reduced accordingly avoidance alcohol recommended due increased risk cns depression well increased risk liver toxicity addition herbal supplement st johns wort may decrease serum levels human experience acute overdose zileuton limited patient clinical study took grams zileuton immediaterelease tablets single dose vomiting inducted patient recovered without sequelae zileuton removed dialysis oral minimum lethal doses mice rats mgkg respectively providing greater times systemic exposure auc achieved maximum recommended human daily oral dose respectively dogs oral dose mgkg providing excess times systemic exposure auc achieved maximum recommended human daily oral dose deaths occurred nephritis reported overdose occur patient treated symptomatically supportive measures instituted required indicated elimination unabsorbed drug achieved emesis gastric lavage usual precautions observed maintain airway certified poison control center consulted uptodate information management overdose zyflo cr httpsenwikipediaorgwikizileuton